Claims for Patent: 8,545,476

Summary for Patent: 8,545,476

Title:	Assembly to facilitate user reconstitution
Abstract:	A reconstitution assembly includes a housing including a lower sleeve and an upper sleeve, including a first container and a second container disposed vertically opposite the first container. A transfer set assembly is disposed within the housing between the first container and the second container. The transfer set assembly includes an upper spike housing and a lower spike housing, with a flow path defined through the upper spike housing and the lower spike housing. The transfer set assembly is configured to access contents of the first container and then upon the activation of a triggering mechanism, create a fluid pathway between the first container and the second container. The triggering mechanism includes trigger fingers which ensure the transfer set assembly sequentially accesses the contents of the first container before accessing the contents of the second container. The disposition of the first container activates the triggering mechanism.
Inventor(s):	Scott R. Ariagno, II Frederick Charles Houghton, Daniel E. Roush
Assignee:	Takeda Pharmaceutical Co Ltd
Application Number:	US13/217,967

Details for Patent 8,545,476

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	July 25, 2003	8,545,476	2031-08-25
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	April 12, 2006	8,545,476	2031-08-25
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	July 03, 2007	8,545,476	2031-08-25
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	July 12, 2012	8,545,476	2031-08-25
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	November 13, 2015	8,545,476	2031-08-25
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	October 25, 2016	8,545,476	2031-08-25
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	March 13, 2017	8,545,476	2031-08-25

International Patent Family for US Patent 8,545,476

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012027563
United States of America	9358181
United States of America	8734420
United States of America	2013334078
United States of America	2012277715
United States of America	2012053555
San Marino	T201700301